Blog

Certainty US 2026 recap: Advancing model-informed drug development right from the start

This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…

Certara2026 年 5 月 26 日

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

Testimonial Video Video

MIDD is Transforming Drug Development

Recorded live at the US Certainty 2026 client conference in Boston, Certara clients who are…

Certara2026 年 5 月 21 日

Guide

如何在药物研发中运用 PBPK 建模与模拟

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

Certara2026 年 5 月 12 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

On-Demand Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Learn how to apply FDA NAM guidance to streamline nonclinical development, support IND decisions, and…

Certara2026 年 5 月 8 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

模型引导的药物开发

Certainty US 2026 recap: Advancing model-informed drug development right from the start

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

MIDD is Transforming Drug Development

如何在药物研发中运用 PBPK 建模与模拟

Minimize risk when preparing for hepatic impairment studies

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

订阅时事通讯

快捷链接

解决方案

联系我们